Three-Month Results of Brolucizumab Intravitreal Therapy in Patients with Wet Age-Related Macular Degeneration

The purpose of the study was to evaluate changes in best corrected visual acuity, central retinal thickness, area and flow in the neovascular membrane and to compare therapeutic outcomes from baseline in patients who received three doses of Beovu (brolucizumab) at three-month follow-up. Material and...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalska-Małecka, Katarzyna, Śpiewak, Dorota, Luksa, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393484/
https://www.ncbi.nlm.nih.gov/pubmed/34444199
http://dx.doi.org/10.3390/ijerph18168450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393484/
https://www.ncbi.nlm.nih.gov/pubmed/34444199
http://dx.doi.org/10.3390/ijerph18168450

Ejemplares similares